Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer

Overview

NCT ID: NCT04527991
Sponsor Protocol Number: IMMU-132-13

About this study

The purpose of this study is to is to evaluate patients with metastatic or locally advanced unresectable urothelial cancer who have progressed after prior therapy with platinum-based regimen and anti-programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Female or male subjects, ≥ 18 years of age, able to understand and give written informed consent.  
  • Subjects with histologically documented metastatic or locally advanced unresectable UC defined as:
    • Tumor (T) 4b, any node (N); or
    • Any T, N 2-3 Tumors of upper and lower urinary tract are permitted. Mixed histologic types are allowed if urothelial is the predominant histology.
  • ECOG performance status (PS) score of 0 or 1.
  • Subjects with progression or recurrence following receipt of platinum-containing  regimen and anti PD-1/PD-L1 therapy for metastatic or locally advanced unresectable  disease will be enrolled:
    • Subjects with recurrence or progression ≤ 12 months following completion of cisplatin-containing chemotherapy given in the neo-adjuvant/adjuvant setting may utilize that line of therapy to be eligible for the study. The 12-month period is counted from completion of surgical intervention or cisplatin therapy, respectively. These subjects must receive anti PD-1/PD-L1 therapy in the metastatic or locally advanced unresectable setting to be eligible;
    • Subjects who received either carboplatin or anti PD-1/PD-L1 therapy in the neo-adjuvant/adjuvant setting will not be able to count that line of therapy towards eligibility for the study;
    • Cisplatin ineligible subjects who meet one of the below criteria and who were treated with carboplatin in the metastatic or locally advanced unresectable settings may count that line of therapy towards eligibility. They must then have received anti PD-1/PD-L1 therapy in metastatic or locally advanced unresectable setting to be eligible for the study.
    • Cisplatin ineligibility is defined as meeting one of the following criteria:  
      • Creatinine Clearance < 60 mL/min;
      • Grade ≥ 2 Audiometric Hearing Loss;
      • Grade ≥ 2 Peripheral Neuropathy;
      • New York Heart Association (NYHA) Class III heart failure;
      • ECOG PS ≥ 2.
    • Anti PD-1/PD-L1 therapy administered as part of maintenance therapy may  be counted towards eligibility for the study;
    • Subjects who have progressed after receiving enfortumab vedotin in prior lines of therapy, and subjects who are either ineligibile or unable tp tolerate enfortumab vedotin therapy, are eligible to enroll in the study;
    • Subjects who received only concurrent  chemoradiation for bladder preservation without further systemic therapy are not  eligible to enroll in the study. The substitution of carboplatin for cisplatin does  not constitute a new regimen provided no new chemo-therapeutic agents were added to the regimen and no progression was noted prior to the change in platinum.
  • Subjects with previously treated brain metastases may participate in the study provided they have stable CNS disease for at least 4 weeks prior to the first dose of study drug and stabilization of all neurologic symptoms, have no evidence of new or enlarging brain metastases, and are not using steroids > 20 mg of prednisone (or equivalent) daily for brain metastases for at least 7 days prior to first dose of the study drug.  
  • Adequate hematologic counts without transfusion or growth factor support within 2 weeks of study drug initiation (hemoglobin ≥ 9 g/dL, absolute neutrophil count [ANC]  ≥ 1,500/mm^3, and platelets ≥ 100,000/µL).  
  • Adequate hepatic function (bilirubin ≤1.5x institutional upper limit of normal [IULN], aspartate aminotransferase [AST] and alanine aminotransferase [ALT] ≤ 2.5 x IULN or  ≤ 5 x IULN if known liver metastases and serum albumin > 3 g/dL).  Docetaxel will only be option in TPC arm for subjects with a total bilirubin ≤ 1 x IULN, and an AST and/or ALT ≤ 1.5 x IULN if alkaline phosphatase is also > 2.5 x IULN.
  • Creatinine clearance ≥ 30 mL/min as assessed by the Cockcroft-Gault equation or other validated instruments (e.g., Modification of Diet in Renal Disease [MDRD] equation).  
  • Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception as described in Appendix 6.

Exclusion Criteria:  

  • Women who are pregnant or lactating. z
  • Have had a prior anti-cancer mAb/ADC within 4 weeks prior to C1D1 or have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to C1D1. Subjects participating in observational studies are eligible.
  • Have received prior chemotherapy for UC with any available SOC therapies in the control arm (i.e., either prior paclitaxel and docetaxel in countries where vinflunine is not an approved therapy, or either prior paclitaxel, docetaxel and vinflunine in countries where vinflunine is approved and is commercially available).
  • Have not recovered (i.e., ≤ Grade 1) from AEs due to previously administered chemotherapeutic agent.
    • Note: Subjects with ≤ Grade 2 neuropathy or any grade of alopecia are an exception to this criterion and will qualify for the study.
    • Note: If subjects received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study therapy.
  • Have previously received topoisomerase 1 inhibitors.
  • Have an active second malignancy.
    • Note: Subjects with a history of malignancy that have been completely treated and with no evidence of active cancer for 3 years prior to enrollment, or subjects with surgically cured tumors with low risk of recurrence are allowed to enroll in the study after discussion with the medical monitor.
  • Have active cardiac disease, defined as:
    • Myocardial infarction or unstable angina pectoris within 6 months of C1D1;
    • History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication); history of QT interval prolongation.
    • NYHA Class III or greater congestive heart failure or left ventricular ejection fraction of < 40%.
  • Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn’s disease) or GI perforation within 6 months of enrollment.
  • Have an active serious infection requiring anti-infective therapy (Contact medical monitor for clarification).
  • Have known history of Human Immunodeficiency Virus (HIV)-1/2 with undetectable viral load and on medications that may interfere with SN-38 metabolism.
  • Have active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV). In subjects with a history of HBV or HCV, subjects with a detectable viral load will be excluded.
  • Have other concurrent medical or psychiatric conditions that, in the investigator’s opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
  • Have inability to tolerate or are allergic to any potential TPC agent or sacituzumab govitecan or unable or unwilling to receive the doses specified in the protocol.
  • Have inability to complete all specified study procedures for any reason.
  • History of active interstitial lung disease or noninfectious pneumonitis.

Eligibility last updated 1/4/22. Questions regarding updates should be directed to the study team contact.

More information

Publications

Publications are currently not available
.
CLS-20522386

Mayo Clinic Footer